Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze REGN stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate REGN investment potential.

What is REGN stock price today?

Get real-time REGN stock price, historical data, and price charts on Financhill. Track REGN performance with our advanced analysis tools.

Is REGN a good investment?

Evaluate REGN investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy REGN stock?

To buy REGN stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of REGN?

View detailed market capitalization data and company valuation metrics for REGN on our comprehensive analysis page.

What is the P/E ratio of REGN?

Use our fundamental analysis tools to view REGN P/E ratio and compare valuation metrics with industry peers.

What are REGN earnings?

View REGN earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Regeneron Pharmaceuticals, Inc. 10K Form

Buy

REGN
Regeneron Pharmaceuticals, Inc.

Last Price:

$722.79

Seasonality Move:

20.45%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02	10Q	REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2023-11-02	10Q	REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2023-08-03	10Q	REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2023-05-04	10Q	REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2022-11-03	10Q	REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2022-08-03	10Q	REGN/Regeneron Pharmaceuticals, Inc. Quarterly

Receive REGN News And Ratings

See the #1 stock for the next 7 days that we like better than REGN

REGN Financial Statistics

Sales & Book Value

Annual Sales:	$14.2B
Cash Flow:	$1.4B
Price / Cash Flow:	20.55
Annual Sales:	$294.00
Price / Book:	2.46

Profitability

EPS (TTM):	41.77010
Net Income (TTM):	$4.6B
Gross Margin:	$11.8B
Return on Equity:	15.37%
Return on Assets:	11.97%

Regeneron Pharmaceuticals, Inc. Earnings Forecast

Key Regeneron Pharmaceuticals, Inc. Financial Ratios

The Gross Profit Margin over the past 35 years for REGN is 82.74%.
The Selling, General & Administrative Expenses for REGN have been equal to 20.80% of Gross Profit Margin.
The Research & Development expenses have been 32.56% of Revenue.
The Interest Expense is 1.25% of Operating Income.
The Net Earning history of REGN is 31.07% of Total Revenues.
Per Share Earnings over the last 35 years have been positive in 19 years.

Regeneron Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	S&P500
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	REGN
CUSIP:	75886F
Website:	regeneron.com

Debt

Debt-to-Equity Ratio:	0.09
Current Ratio:	4.06
Quick Ratio:	3.19

Price-to-Earnings

Trailing P/E Ratio:	18.88
Forward P/E Ratio:	16.72

REGN Technical Analysis vs Fundamental Analysis

Buy

Regeneron Pharmaceuticals, Inc. (REGN) is a Buy

Is Regeneron Pharmaceuticals, Inc. a Buy or a Sell?

Regeneron Pharmaceuticals, Inc. stock is rated a Buy

The current Regeneron Pharmaceuticals, Inc. [REGN] share price is $722.80. The Score for REGN is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.